Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sipai Health Technology CoHKSE:00314 +1.62%60 Buyback Yield % is 19.66 as of Sep. 06, 2026, which is 908% above its 10-year median of 1.95. GuruFocus rates HKSE:00314 with a GF Score™ of 60/100 and a GF Value™ of HK$2.37 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 34 Medical Distribution companies, Sipai Health Technology Co ranks better than 97.06% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00314 vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Sipai Health Technology Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sipai Health Technology Co Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Sipai Health Technology Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sipai Health Technology Co (HKSE:00314) has a Buyback Yield % of 19.66 as of Sep. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sipai Health Technology Co and its competitors. This is 908% above median its historical median of 1.95. According to the industry distribution chart, Sipai Health Technology Co ranks #1 out of 34 companies in the Medical Distribution industry, placing it in the top 2.9%.
Is Sipai Health Technology Co's Buyback Yield % too high?
Sipai Health Technology Co's current Buyback Yield % of 19.66 is 908% above median its 10-year median of 1.95. The Medical Distribution industry median Buyback Yield % is 0.36. Sipai Health Technology Co's value of 19.66 is 5361.1% above this industry median. Based on the distribution chart, Sipai Health Technology Co ranks #1 out of 34 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sipai Health Technology Co has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sipai Health Technology Co's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sipai Health Technology Co ranks #1 out of 34 companies for Buyback Yield %. This places Sipai Health Technology Co in the top 3% of its industry — outperforming the majority of peers. The industry median Buyback Yield % is 0.36. Sipai Health Technology Co's value of 19.66 is 5361.1% above this benchmark. While the company's 10-year median is 1.95 vs. the industry median of 0.36, Sipai Health Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
The median Buyback Yield % among Medical Distribution companies is 0.36, based on 34 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sipai Health Technology Co's current Buyback Yield % of 19.66 is 5361.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sipai Health Technology Co and its competitors. For the Medical Distribution industry, the median Buyback Yield % is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sipai Health Technology Co's current Buyback Yield % is 19.66, which is 908% above median its own 10-year median of 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sipai Health Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Sipai Health Technology Co (HKSE:00314) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.37, compared to a current price of HK$1.57 — trading 34% below its estimated fair value. The current Buyback Yield % is 19.66, which is 908% above median its 10-year median of 1.95 and 5361.1% above the Medical Distribution industry median of 0.36. Sipai Health Technology Co's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sipai Health Technology Co (HKSE:00314), the current Buyback Yield % is 19.66 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sipai Health Technology Co (HKSE:00314) Overvalued in 2026?
Based on GuruFocus' analysis, Sipai Health Technology Co stock appears to be undervalued.
The current stock price of HK$1.57 is trading 34% below its estimated GF Value™ of HK$2.37.
GuruFocus considers Sipai Health Technology Co to be Possible Value Trap.
Key valuation signals for HKSE:00314:
Buyback Yield %: 19.66 (908% above median its 10-year median of 1.95)
GF Value™: HK$2.37 vs. price of HK$1.57 (34% below fair value)
Industry Position: 5361.1% above the Medical Distribution median (#1 of 34)
No single metric tells the full story. See the HKSE:00314 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sipai Health Technology Co Ltd is a medical technology and health management company in China. The company has three reportable operating segments: Specialty Pharmacy Business - engaged in the operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Commercial Insurance Services Business - rendering insurance brokerage services to insurance companies and health management services to insurance carriers and enterprise clients. The company generates key revenue from the Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.
60GF Score
Get the complete analysis for HKSE:00314
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00314 has been successfully added to your 
